Should Metabolic Imaging to Assess Minimal Residual Disease (MRD) Become a Clinical Endpoint in Multiple Myeloma?
Normalization of PET-CT is a strong predictor\xa0 \xa0for progression free survival (PFS) and overall survival (OS) in multiple myeloma (MM) Related Article:\xa0Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study